Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform
14 Giugno 2021 - 5:45PM
Business Wire
Launch of the new system is part of the
company’s mission to deliver an enhanced platform combining
advanced imaging, digital health informatics, and improved patient
outcomes
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY)
(Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary
probe and needle-based confocal laser endomicroscopy (p/nCLE)
platform, today unveiled the next-generation Cellvizio platform,
which has already received both 510(k) clearance (K193416) from the
U.S. Food and Drug Administration (FDA) and CE marking. Built with
enhanced capabilities, this entirely new system uses the company’s
proprietary Confocal Laser Endomicroscopy (CLE) advanced imaging
technology to deliver cellular and molecular imaging virtually
anywhere in the human body, and will be available for purchase in
the second half of 2021.
Building upon the success of the previous models, the new
generation of Cellvizio equips physicians with the most advanced
cellular imaging technology to improve patients’ lives. The
platform includes several new features: an all-new workflow
integration for endoscopic, bronchoscopic, or operating
environments via integrated connectivity; enhanced capabilities
enabling artificial intelligence (AI) for assisted pattern
recognition; and a small footprint and slim profile allowing easy
maneuverability within the procedure room.
“Our next-generation platform represents a tremendous leap
forward in product innovation that significantly improves the ease
of integrating Cellvizio into procedure rooms around the world,”
said Robert L. Gershon, Chief Executive Officer of Mauna Kea
Technologies. “The system readiness to host novel advanced
capabilities, particularly artificial intelligence, will expand our
ability to provide advanced imaging techniques and real-time
digital health informatics as part of the overall delivery of
patient care.”
Learn more by visiting:
www.landing.maunakeatech.com/next-gen-cellvizio
About Mauna Kea Technologies Mauna Kea Technologies is a
global medical device company that manufactures and sells
Cellvizio®, the real-time in vivo cellular imaging platform. This
technology uniquely delivers in vivo cellular visualization which
enables physicians to monitor the progression of disease over time,
assess point-in-time reactions as they happen in real-time,
classify indeterminate areas of concern, and guide surgical
interventions. The Cellvizio platform is used globally across a
wide range of medical specialties and is revolutionizing the way
physicians diagnose and treat patients — making a transformative
change in medicine. For more information, visit
www.maunakeatech.com.
Disclaimer This press release contains forward-looking
statements concerning Mauna Kea Technologies and its activities.
Such forward looking statements are based on assumptions that Mauna
Kea Technologies considers to be reasonable. However, there can be
no assurance that the anticipated events contained in such
forward-looking statements will occur. Forward- looking statements
are subject to numerous risks and uncertainties including the risks
set forth in the Universal Registration Document of Mauna Kea
Technologies registered by the French Financial Markets Authority
(Autorité des marchés financiers (AMF)) on August 7, 2020 under
number 926346434_20200807 and available on the Company's website
(www.maunakeatech.com), and to the development of economic
situation, financial markets, and the markets in which Mauna Kea
Technologies operates. The forward-looking statements contained in
this release are also subject to risks unknown to Mauna Kea
Technologies or that Mauna Kea Technologies does not consider
material at this time. The realization of all or part of these
risks could lead to actual results, financial conditions,
performances or achievements by Mauna Kea Technologies that differ
significantly from the results, financial conditions, performances
or achievements expressed in such forward-looking statements. This
press release and the information it contains do not constitute an
offer to sell or to subscribe for, or a solicitation of an order to
purchase or subscribe for, Mauna Kea Technologies shares in any
country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210614005385/en/
United States Mike
Piccinino, CFA Westwicke, an ICR Company 443-213-0500
France and Europe NewCap -
Investor Relations Thomas Grojean +33 (0)1 44 71 94 94
maunakea@newcap.eu